Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
NARRATIVE VELOCITY ENGINE

Neurocompute

AI-driven Parkinson’s research intelligence platform exploring emerging signals, forgotten papers, and therapeutic patterns across the biomedical literature universe.

Indexed Papers
1,516
AI Scored
984
Ranked Papers
998
Coverage
1.3%
RESEARCH INTELLIGENCE BOARD

Ranked Parkinson’s Papers

1516 results
LAST INGEST 2026-05-29 06:45 PM
E
ASL/ALT Ratio in Familial and Sporadic Parkinson's Disease: Insights From Cross-Sectional Logistic Analysis.
PMID 42021494 Published: 2026-04-01 Ingested: 2026-04-28 08:58 PM Brain and behavior
AI 36.0
Base 30.8
Rank 29.2
AI Summary

Retrospective analysis of 1,315 PPMI participants found a nonlinear association between serum AST/ALT ratio and familial versus sporadic PD—strong above a threshold of 1.503—with a predictive model AUC of 0.758.

Why It Matters

AST/ALT is an inexpensive, routinely available serum marker that could aid PD subtyping and trial stratification, offering translational potential despite limited mechanistic insight and the need for prospective validation.

E
A Collaborative Approach to Creating Knowledge-Building Resources for the Early-Stage Parkinson's Disease Community.
PMID 42048010 Published: 2026-04-28 Ingested: 2026-04-28 08:58 PM Neurology and therapy
AI 35.0
Base 30.8
Rank 29.2
AI Summary

This paper describes an industry–patient–advocacy collaboration that developed and refined educational materials and a knowledge-building guide to improve understanding of disease‑modifying therapies among people with early‑stage Parkinson’s, raising measured health literacy and readability.

Why It Matters

While it contains no mechanistic or therapeutic findings, improving patient literacy and engagement around DMTs can boost recruitment, informed consent, and trial readiness—indirectly accelerating Parkinson’s therapeutic development.

E
Safety and Efficacy of Focused Ultrasound Thalamotomy in Elderly Patients: A Single-Center Cohort Study.
PMID 41952374 Published: 2026-04-08 Ingested: 2026-04-28 08:58 PM Movement disorders clinical practice
AI 35.0
Base 30.8
Rank 29.2
AI Summary

Retrospective single-center study finds MRgFUS thalamotomy yields sustained, >50% tremor reduction with comparable safety and side-effect resolution in patients ≥80 versus younger patients.

Why It Matters

Supports expanding a noninvasive, symptomatic treatment option to carefully selected very elderly patients with tremor-predominant Parkinson's disease, increasing clinical applicability though it offers no disease-modifying insights.

E
Up-regulation of tRNA-derived miR-1274b in tears of Parkinson's disease patients.
PMID 41962421 Published: 2026-04-05 Ingested: 2026-04-28 08:58 PM Parkinsonism & related disorders
AI 35.0
Base 30.8
Rank 29.2
AI Summary

The study reports consistent up-regulation of tRNA-derived miR-1274b in tear fluid from small PD cohorts, with in-silico predicted targets and network links to synaptic regulation and PD-related genes.

Why It Matters

Identifies a non-invasive biomarker candidate that could aid diagnosis or stratification, though small sample sizes and no functional validation limit immediate therapeutic or mechanistic utility.

E
Relationship Between Neurologic Symptoms and Signs and FMR1 Genotype in Premutation Carriers.
PMID 41917775 Published: 2026-03-31 Ingested: 2026-04-28 08:58 PM Annals of clinical and translational neurology
AI 35.0
Base 30.8
Rank 29.2
AI Summary

In 176 FMR1 premutation carriers the authors report a linear relationship between CGG repeat length and FMR1 mRNA levels and show that larger repeats associate with greater neurological severity, with Parkinsonism and cognitive impairment significantly correlated with CGG size in males.

Why It Matters

This links an RNA/toxic-gain-of-function mechanism and a genetic biomarker to parkinsonian manifestations in a defined subpopulation, which could help stratify patients or suggest mechanistic parallels for targeted research, but it offers limited immediate translational value for typical…

E
AI 35.0
Base 30.8
Rank 29.2
AI Summary

PD patients show a prolonged phase-average wavelength of alpha EEG rhythm—greater in those with cognitive impairment—and this measure correlates negatively with cognitive test scores.

Why It Matters

Identifies a noninvasive EEG biomarker that could help detect and track cognitive decline and stratify patients in clinical studies, offering translational utility for outcome measurement though it does not directly inform molecular therapeutic targets.

E
SNCA Overexpression Induces Apoptosis in Non-Small Cell Lung Cancer via Caspase-Dependent Signaling Pathways.
PMID 41983437 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM BioMed research international
AI 35.0
Base 30.8
Rank 29.2
AI Summary

Overexpressing alpha-synuclein (SNCA) in non-small cell lung cancer cell lines increases oxidative stress and triggers caspase-dependent apoptosis, with squamous-cell lines more sensitive than adenocarcinoma lines.

Why It Matters

Offers mechanistic cellular evidence that SNCA overexpression drives mitochondrial/oxidative-stress–linked, caspase-mediated cell death—insightful for understanding alpha-synuclein toxicity relevant to Parkinson's disease biology but of limited direct translational value because the work is in…

E
Corneal epithelial thickness can reflect the stage of Parkinson's disease and the severity of dry eye.
PMID 41959662 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in aging neuroscience
AI 35.0
Base 30.8
Rank 29.2
AI Summary

This cross-sectional study found corneal epithelial thinning measured by AS-OCT correlates with dry eye severity and Hoehn & Yahr stage in Parkinson's patients.

Why It Matters

Zonal corneal epithelial thickness mapping is a non-invasive biomarker candidate that could help disease staging and patient stratification in trials, but it offers limited direct mechanistic or therapeutic insight for Parkinson's drug discovery.

E
Multimodal Integration of A Novel Gait State Time Interval Signal Generation Method and Insole Sensor Data-based Body Intelligence: Application in Parkinson's Disease.
PMID 42019073 Published: 2026-04-22 Ingested: 2026-04-28 08:58 PM IEEE journal of biomedical and health informatics
AI 32.0
Base 30.8
Rank 29.2
AI Summary

Introduces a novel gait-state time-interval (GSTI) signal derived from multizonal plantar load distribution and an Integrative Body Intelligence framework using spectral/bispectral features from insole sensors to classify Parkinson's disease with 94.44% accuracy and enable acoustic/visual…

Why It Matters

Provides a promising noninvasive wearable method for early PD detection and individualized gait rehabilitation that could aid monitoring and trial stratification, but it offers little mechanistic or therapeutic-target insight for drug discovery.

E
Hierarchical Coarse-to-Fine cGAN for Subtype-Specific Freezing of Gait Signal Generation.
PMID 42009321 Published: 2026-04-20 Ingested: 2026-04-28 08:58 PM IEEE journal of biomedical and health informatics
AI 32.0
Base 30.8
Rank 29.2
AI Summary

The paper introduces a hierarchical coarse-to-fine conditional GAN that generates realistic, subtype-conditioned ankle-acceleration signals for the three FOG subtypes (shuffling, trembling, akinesia) to augment training data and substantially improve CNN-based FOG detection, particularly for…

Why It Matters

Although it does not advance disease mechanisms or therapies directly, subtype-aware augmentation tackles data scarcity and class imbalance to enable more reliable, personalized FOG phenotyping and monitoring, which can improve outcome measurement and model-based endpoints in clinical studies and…

E
Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort.
PMID 41995451 Published: 2026-04-17 Ingested: 2026-04-28 08:58 PM Journal of Parkinson's disease
AI 32.0
Base 30.8
Rank 29.2
AI Summary

Largest LATAM cohort study of levodopa-induced dyskinesia (LID) finding 25.4% prevalence overall (range 9.3–45.1%), increasing with disease duration, with fast progression but not sex associated with higher LID risk.

Why It Matters

Provides population-specific epidemiologic data that can guide risk stratification, trial design, and motivate integration of genetic and environmental studies to uncover LID mechanisms relevant to diverse populations.

E
The effect of coffee consumption and smoking on cognitive function in early Parkinson's disease.
PMID 42013784 Published: 2026-04-15 Ingested: 2026-04-28 08:58 PM Parkinsonism & related disorders
AI 32.0
Base 30.8
Rank 29.2
AI Summary

Observational study of 149 early PD patients found that higher coffee consumption (especially >1 cup/day) was modestly associated with better performance on select executive function tests (Go-No-Go, Calculation, Contrasting Program) after covariate adjustment, while smoking showed no cognitive…

Why It Matters

Indicates caffeine might modestly correlate with preserved executive function in early PD, providing a low-risk repurposing hypothesis and justification for targeted replication and mechanistic studies relevant to symptomatic cognitive management.

E
Perceptual Training for People With Parkinson's Disease.
PMID 41984773 Published: 2026-04-15 Ingested: 2026-04-28 08:58 PM American journal of speech-language pathology
AI 32.0
Base 30.8
Rank 29.2
AI Summary

Phase 1 trial shows adults with Parkinson's disease can significantly improve recognition of hypokinetic dysarthric speech through a validated listener-focused perceptual training protocol, with gains comparable to neurotypical listeners.

Why It Matters

Although not disease-modifying, this feasible behavioral intervention has clear translational value for improving communication, social participation, and quality of life in people with PD, making it clinically relevant for symptomatic management.

E
AI 32.0
Base 30.8
Rank 29.2
AI Summary

The study implements a scalable high-throughput, high-content C. elegans imaging workflow to quantify dopaminergic neuron degeneration and dopamine-dependent behavioral deficits after exposure to several PFAS compounds and mixtures, identifying PFOS as the most potent and mixture toxicity driven by…

Why It Matters

It provides a rapid in vivo screening platform to prioritize environmental chemicals that cause dopaminergic neurotoxicity—useful for flagging agents for further mechanistic or mammalian follow-up studies related to PD risk, though it offers limited direct therapeutic targets or clinical…

E
AI 32.0
Base 30.8
Rank 29.2
AI Summary

In a cross-sectional cohort of 60 older adults, Parkinson's disease was associated with prolonged contraction time and reduced maximal muscle displacement in the lateral gastrocnemius (TMG), whereas sarcopenic participants had substantially lower hip and knee extension isometric strength.

Why It Matters

The paper highlights distinct, measurable peripheral muscle phenotypes in PD versus sarcopenia that could inform functional biomarkers and guide targeted rehabilitation or monitoring, but it provides limited mechanistic or drug-target insights for therapeutic discovery.

E
Classification of fall risk in Parkinson's disease using empirical mode decomposition and machine learning.
PMID 41938060 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in bioengineering and biotechnology
AI 32.0
Base 30.8
Rank 29.2
AI Summary

This study used empirical mode decomposition of center-of-pressure signals and machine learning (SFFS feature selection plus classifiers) to classify fall risk in 32 PD patients, identifying a 3-feature subset and achieving up to 0.96 subject-level AUC in the best condition.

Why It Matters

Offers a robust, objective monitoring/stratification tool for fall risk and potential clinical-trial endpoints in PD, improving assessment and remote monitoring, but provides little direct mechanistic or therapeutic discovery insight.

E
Virtual vs In-Person Neurologic Ambulatory Care: A Case-Control Study of Subsequent Health Care Utilization.
PMID 42018961 Published: 2026-05-26 Ingested: 2026-04-28 08:58 PM Neurology
AI 31.0
Base 30.8
Rank 29.2
AI Summary

In a propensity-matched multicenter cohort comparing 8,202 virtual to 8,202 in-person new neurology visits, overall 90-day neurologic follow-up, ED visits, and hospitalizations were similar, though Parkinson disease visits showed higher short-term follow-up after virtual encounters and some testing…

Why It Matters

This supports telemedicine as a safe, pragmatic approach for initial Parkinson care and remote follow-up and could facilitate trial recruitment and decentralized monitoring, but it provides minimal direct insight for mechanistic or therapeutic discovery.

E
AI 31.0
Base 30.8
Rank 29.2
AI Summary

The study applied NMF and multimodal matrix factorization to EMG and joint angular-acceleration data from 19 Parkinson's patients during walking, extracting four EMG synergies and eight cross-modal synergies that link specific muscle groups (e.g., TA, SOL, RF) with pelvis-to-lower-limb kinematic…

Why It Matters

While not identifying molecular targets, the joint EMG–kinematic synergy framework offers quantitative, potentially clinically actionable biomarkers for stratifying gait phenotypes, tracking motor progression, and evaluating rehabilitation or neuromodulation interventions in PD.

E
Cortical gyrification deficits in early-stage Parkinson's disease: the importance of bradykinesia.
PMID 41924695 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Brain communications
AI 30.8
Base 30.8
Rank 29.2
AI Summary

MRI analysis of early-stage Parkinson's patients found reduced cortical gyrification in left parahippocampal and lingual gyri and gyrification deficits in right parietal, temporal, and occipital regions that correlate with bradykinesia and functional capacity.

Why It Matters

Suggests cortical gyrification could serve as a noninvasive biomarker for early diagnosis or progression monitoring linked to motor severity, but offers limited direct therapeutic or mechanistic targets for drug discovery.

E
Dopaminergic modulation of the sense of agency influences moral behavior in Parkinson's disease.
PMID 42008672 Published: 2026-04-28 Ingested: 2026-04-28 08:58 PM Proceedings of the National Academy of Sciences of the United States of America
AI 30.0
Base 30.8
Rank 29.2
AI Summary

In PD patients tested ON vs OFF dopaminergic medication and healthy controls, dopaminergic treatment increased perceived sense of agency—especially when actions matched but failed goals—reduced self-serving dishonest choices, and altered evidence accumulation for agency judgments linked to…

Why It Matters

The study shows how dopaminergic therapy modulates corporeal self-awareness and moral decision-making, which can inform clinical management of cognitive/behavioral effects of dopaminergic drugs, but it offers limited direct leads for disease-modifying or target-based therapeutic discovery.

E
The Relationship between Clinical Measures of Dysphagia, Self-Reported Symptoms, and Cognition in People with Parkinson's Disease.
PMID 42030220 Published: 2026-04-24 Ingested: 2026-04-28 08:58 PM Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)
AI 30.0
Base 30.8
Rank 29.2
AI Summary

In 52 people with Parkinson's, cognition was not associated with objective or subjective dysphagia, but prolonged water-swallowing time correlated with self-reported swallowing problems and interacted with cognition.

Why It Matters

The paper has limited therapeutic-discovery value but is clinically relevant: it highlights water-swallowing testing as a useful assessment metric and warns clinicians that intact cognition does not rule out dysphagia, informing patient evaluation and outcome measurement.

E
AI 30.0
Base 30.8
Rank 29.2
AI Summary

A Spanish PRISM real-world survey of 149 people with Parkinson's and 38 caregivers found high motor and non-motor symptom burden, widespread levodopa use, a 57% rate of reported impulse control behaviors, low use of rehabilitation therapies, and strong interest but low participation in clinical…

Why It Matters

While not providing mechanistic or therapeutic leads, the dataset identifies clear unmet clinical needs, high non-motor and impulse-control symptom prevalence, and potential opportunities to improve care delivery and design/target recruitment for interventional trials in Spain.

E
Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism.
PMID 41918506 Published: 2026-03-01 Ingested: 2026-04-28 08:58 PM The Yale journal of biology and medicine
AI 30.0
Base 30.8
Rank 29.2
AI Summary

This study identifies a homozygous PTRHD1 (c.155G>A, p.Cys52Tyr) mutation in a family with early intellectual disability and later-onset atypical parkinsonism, expanding the clinical phenotype and showing widespread PTRHD1 expression in adult brain.

Why It Matters

It implicates PTRHD1 as a rare monogenic contributor to neurodevelopmental and neurodegenerative phenotypes—valuable for genetic classification and hypothesis generation but of limited immediate translational or therapeutic relevance without mechanistic links to established Parkinson's pathways.

E
Cognitive and affective Theory of Mind abilities in Parkinson's disease before and 1 year after subthalamic deep brain stimulation.
PMID 41947869 Published: 2026-01-01 Ingested: 2026-04-28 08:58 PM Frontiers in human neuroscience
AI 30.0
Base 30.8
Rank 29.2
AI Summary

Prospective study of 27 PD patients found cognitive and affective Theory of Mind abilities largely unchanged one year after bilateral subthalamic deep brain stimulation, with ToM performance correlating with overall cognition and specific neuropsychological domains.

Why It Matters

This supports the cognitive/ToM safety profile of STN-DBS and helps guide patient counseling and selection, but provides limited mechanistic or therapeutic-discovery insights for Parkinson's disease drug development.

E
An enhanced framework for Parkinson's disease severity prediction using improved optimization in multi-scale TCN.
PMID 41980315 Published: 2026-04-03 Ingested: 2026-04-28 08:58 PM Computational biology and chemistry
AI 28.0
Base 30.8
Rank 29.2
AI Summary

This study presents an automated Parkinson's disease severity prediction framework that combines ensemble feature extraction (IAOA-weighted features, RBM, t-SNE) with an Adaptive Multi-scale Temporal Convolutional Network (AMTCN) to classify UPDRS-based severity, reporting ~94% accuracy.

Why It Matters

Improved and more interpretable severity prediction can aid clinical monitoring, patient stratification, and trial enrollment, but the work offers little direct mechanistic or therapeutic insight for drug discovery.

Previous
Page 27 of 61
Next
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic